Cargando…

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus

INTRODUCTION: Two studies were carried out to investigate the efficacy and safety of luseogliflozin added to existing oral antidiabetic drugs (OADs) in Japanese type 2 diabetic patients inadequately controlled with OAD monotherapy. MATERIALS AND METHODS: In the trial involving add-on to sulfonylurea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seino, Yutaka, Inagaki, Nobuya, Haneda, Masakazu, Kaku, Kohei, Sasaki, Takashi, Fukatsu, Atsushi, Ubukata, Michito, Sakai, Soichi, Samukawa, Yoshishige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511304/ https://www.ncbi.nlm.nih.gov/pubmed/26221523 http://dx.doi.org/10.1111/jdi.12316

Ejemplares similares

Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males
por: Sasaki, Takashi, et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
por: Samukawa, Yoshishige, et al.
Publicado: (2018)

Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2014)

Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects
por: Kumagai, Yuji, et al.
Publicado: (2015)

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study
por: Samukawa, Yoshishige, et al.
Publicado: (2016)

Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study
por: Seino, Yutaka, et al.
Publicado: (2017)

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus
por: Jinnouchi, Hideaki, et al.
Publicado: (2016)

Sodium‐glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low‐carbohydrate diet
por: Nishimura, R., et al.
Publicado: (2016)

Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study
por: Nishimura, R., et al.
Publicado: (2015)

Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study
por: Shirai, Kohji, et al.
Publicado: (2018)

Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study
por: Shirai, Kohji, et al.
Publicado: (2018)

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study
por: Seino, Yutaka, et al.
Publicado: (2012)

Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy
por: Kaku, Kohei, et al.
Publicado: (2014)

Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial
por: Kiyosue, Arihiro, et al.
Publicado: (2017)

Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical trial
por: Kaneko, Shizuka, et al.
Publicado: (2018)

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial
por: Kaku, Kohei, et al.
Publicado: (2015)

Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials
por: Sano, Motoaki, et al.
Publicado: (2018)

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
por: Chino, Yukihiro, et al.
Publicado: (2014)

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus
por: Seino, Yutaka, et al.
Publicado: (2010)

Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
por: Seino, Hiroaki
Publicado: (2021)

Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus
por: Nakamura, Jiro, et al.
Publicado: (2017)

Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
por: Seino, Hiroaki
Publicado: (2021)

The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2012)

Influence of Luseogliflozin on Vaginal Bacterial and Fungal Populations in Japanese Patients With Type 2 Diabetes
por: Kusunoki, Masataka, et al.
Publicado: (2021)

Glucagon‐like peptide‐1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52‐week, randomized, multicenter trial
por: Seino, Yutaka, et al.
Publicado: (2011)

Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early‐stage type 2 diabetes
por: Hirukawa, Hidenori, et al.
Publicado: (2018)

Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats
por: Xie, Keyu, et al.
Publicado: (2023)

A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control
por: Kadowaki, Takashi, et al.
Publicado: (2021)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
por: Yabe, Daisuke, et al.
Publicado: (2022)

Evaluation of potential activity of luseogliflozin on vascular proliferation in the mesenteric lymph node with or without vascular tumors in Sprague-Dawley rats in a carcinogenicity study
por: Sasaki, Minoru, et al.
Publicado: (2016)

Efficacy and safety of once‐weekly oral trelagliptin switched from once‐daily dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: An open‐label, phase 3 exploratory study
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open‐label, multicenter study
por: Seino, Yutaka, et al.
Publicado: (2017)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Solid‐phase extraction treatment is required for measurement of active glucagon‐like peptide‐1 by enzyme‐linked immunosorbent assay kit affected by heterophilic antibodies
por: Hasegawa, Tomonori, et al.
Publicado: (2018)

Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction
por: Nakashima, Mitsutaka, et al.
Publicado: (2021)

Fifty‐two‐week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon‐like peptide‐1 analog liraglutide vs glibenclamide in patients with type 2 diabetes
por: Kaku, Kohei, et al.
Publicado: (2011)

Analysis of factors influencing postprandial C‐peptide levels in Japanese patients with type 2 diabetes: Comparison with C‐peptide levels after glucagon load
por: Funakoshi, Shogo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_84bjh2vo08dp2pdtb6m5vsqmoa